Sergio Marchini - Istituto Clinico Humanitas IRCCS

基本信息

浏览量：60

职业迁徙

个人简介

Sergio Marchini currently works at the Department of Cancer Pharmacology, IRCCS Humanitas Research Hospital, and he is the Head of Molecular Pharamcology Lab. The main research activity is in the field of Translational Research

研究兴趣

论文共 202 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

SAMURAI: Shallow Analysis of Copy Number Alterations Using a Reproducible and Integrated Bioinformatics Pipeline

Sara Potente, Diego Boscarino, Dino Paladin,Sergio Marchini,Luca Beltrame,Chiara Romualdi

BRIEFINGS IN BIOINFORMATICSno. 1 (2025)

引用0浏览0WOS引用

Immune Evasion Mechanisms in Early-Stage I High-Grade Serous Ovarian Carcinoma: Insights into Regulatory T Cell Dynamics

Joanna Mikulak,Sara Terzoli, Paolo Marzano, Valentina Cazzetta, Giampaolo Martiniello,Rocco Piazza, Maria Estefania Viano,Domenico Vitobello,Rosalba Portuesi,Fabio Grizzi, A,Barbara Fiamengo,Gianluca Basso, Lara Parachini,Laura Mannarino,Maurizio D'Incalci,Sergio Marchini,Domenico Mavilio

Cell death & disease（2025）

引用0浏览0WOSNATURE引用

Unraveling the Complexity of HRD Assessment in Ovarian Cancer by Combining Genomic and Functional Approaches: Translational Analyses of MITO16-MaNGO-OV-2 Trial

B. Pellegrino,E. D. Capoluongo,M. Bagnoli,L. Arenare,D. Califano, G. Scambia,S. C. Cecere,E. M. Silini,G. L. Scaglione, A. Spina, G. Tognon,N. Campanini,C. Pisano,D. Russo, A. Pettinato,P. Scollo, R. Iemmolo,L. De Cecco,A. Musolino,S. Marchini,L. Beltrame,L. Paracchini,F. Perrone,D. Mezzanzanica,S. Pignata

ESMO OPENno. 1 (2025)

引用0浏览0WOS引用

Abstract A062: Untargeted Analysis of Plasma Tumor Fraction is an Independent Prognostic Marker of Response to Front Line Chemotherapy in High-Grade Serous Epithelial Ovarian Cancer: the MITO-16A/MANGO-OV2A Clinical Trial Experience

Sergio Marchini,Lara Paracchini,Laura Arenare,Giovanni Scambia,Carmela Pisano, Riccardo Zadro,Laura Mannarino,Annamaria Ferrero,Paolo Chiodini,Daniela Califano,Piergiacomo Di Gennaro,Sandro Pignata,Maurizio D'Incalci

Cancer Researchno. 5_Supplement_2 (2024)

引用0浏览0引用

In-Silico Identification of Novel Pharmacological Synergisms: the Trabectedin Case

Laura Mannarino, Nicholas Ravasio,Maurizio D'Incalci,Sergio Marchini,Marco Masseroli

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCESno. 4 (2024)

引用0浏览0WOS引用

A Phase IV Trial to Confirm the Efficacy of Olaparib in Combination with Bevacizumab As Maintenance Frontline Treatment of HRD-positive Ovarian Tumours (Iolanthe)

Federica Tomao,Lara Paracchini,Chiara Battistini,Nicoletta Colombo,Ugo Cavallaro, Giuseppe Funari,Annamaria Ferrero,Giulia Tasca,Monica Giordano,Federica Villa,Editta Baldini,Maria Cristina Petrella,Elisa Gasparini, Silvia Derio,Fulvio Borella,Maria Francesca Alvisi, Niccolo Biagi, Thu Hoai Dang,Sergio Marchini,Elena Biagioli

Journal of Clinical Oncologyno. 16_suppl (2024): TPS5628-TPS5628

引用0浏览0引用

C/EBPβ-dependent Autophagy Inhibition Hinders NK Cell Function in Cancer

NATURE COMMUNICATIONSno. 1 (2024)

引用0浏览0WOSNATURE引用

Mechanism of Efficacy of Trabectedin Against Myxoid Liposarcoma Entails Detachment of the FUS-DDIT3 Transcription Factor from Its DNA Binding Sites

Ilaria Craparotta,Laura Mannarino, Riccardo Zadro,Sara Ballabio,Sergio Marchini,Giulio Pavesi, Marta Russo,Salvatore Lorenzo Renne,Marina Meroni,Marianna Ponzo,Ezia Bello,Roberta Sanfilippo,Paolo G. Casali,Maurizio D’Incalci,Roberta Frapolli

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCHno. 1 (2024)

引用0浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn